Pelvic floor muscle training versus watchful waiting or pessary treatment for pelvic organ prolapse (POPPS): design and participant baseline characteristics of two parallel pragmatic randomized controlled trials in primary care.

M. Wiegersma,C. Panman,B. Kollen,K. Vermeulen,Aaltje J Schram,E. Messelink,M. Berger,Yvonne Lisman-van Leeuwen,J. Dekker

DOI: https://doi.org/10.1016/j.maturitas.2013.10.014

IF: 5.11

2014-02-01

Maturitas

Abstract:

What problem does this paper attempt to address?

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma

Nicholas H. Chakiryan,Ali Hajiran,Young‐Chul Kim,Ahmet Aydın,Logan Zemp,Esther N. Katende,Jonathan V. Nguyen,Wenyi Fan,Chia‐Ho Cheng,Neale Lopez-Blanco,Jad Chahoud,Philippe E. Spiess,Michelle Fournier,Jasreman Dhillon,Liang Wang,Carlos Moran-Segura,James J. Mulé,Dongliang Du,Sean Yoder,Anders Berglund,Jamie K. Teer,Brandon J. Manley

DOI: https://doi.org/10.1016/j.euf.2021.04.014

IF: 5.952

2022-01-01

European Urology Focus

Abstract:Background Clear cell renal cell carcinoma (ccRCC) tumors have low frequencies of genetic alterations compared with other malignancies, but very high levels of immune cell infiltration and favorable response rates to immunotherapy. Currently, the interplay between specific ccRCC somatic mutations and immune infiltration pattern is unclear. Objective To analyze the associations between common ccRCC somatic mutations and immune cell infiltration patterns within the tumor immune microenvironment (TIME). Design, setting, and participants The study included tumor samples (24 primary and 24 metastatic) from 48 patients with stage IV ccRCC. Targeted sequencing was performed for well-characterized recurrent somatic mutations in ccRCC, with the analysis focusing on the six most common ones: VHL, BAP1, PBRM1, SETD2, TP53, and KDM5C. For each sample, multiplex immunofluorescence (IF) was performed in lymphoid and myeloid panels, for seven regions of interest in three zones (tumor core, stroma, and tumor-stroma interface). IF-derived cellular densities were compared across patients, stratified by their somatic mutation status, using a linear mixed-model analysis. External validation was pursued using RNA-seq enrichment scoring from three large external data sources. Results and limitations Tumors with SETD2 mutations demonstrated significantly decreased levels of FOXP3+ T cells in the tumor core, stroma, and tumor-stroma interface. PBRM1 mutations were associated with decreased FOXP3+ T cells in the tumor core. Primary KDM5C mutations were associated with significantly increased CD206+ macrophage tumor infiltration in the tumor core. A computational method estimating immune cell types in the TIME using bulk RNA-seq data, xCell scoring, failed to validate associations from the IF analysis in large external data sets. A major limitation of the study is the relatively small patient population studied. Conclusions This study provides evidence that common somatic mutations in ccRCC, such as SETD2, PBRM1, and KDM5C, are associated with distinct immune infiltration patterns within the TIME. Patient summary In this study, we analyzed tumor samples from patients with metastatic kidney cancer to determine whether common genetic mutations that arise from the cancer cells are associated with the density of immune cells found within those tumors. We found several distinct immune cell patterns that were associated with specific genetic mutations. These findings provide insight into the interaction between cancer genetics and the immune system in kidney cancer.
Letter to the Editor: Effect of Parathyroidectomy on Renal Function: Dichotomous Results and Confusing Conclusions.

P. Kulkarni,Sharon W. Lahiri,Sudhaker D. Rao

DOI: https://doi.org/10.1210/jc.2015-3936

2016-02-03

Abstract:
Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions

Shenglin Mei,Adele M. Alchahin,Ioanna Tsea,Youmna Kfoury,Taghreed Hirz,Nathan Elias Jeffries,Ting Zhao,Yanxin Xu,Hanyu Zhang,Hirak Sarkar,Shulin Wu,Alexander O. Subtelny,John Inge Johnsen,Yida Zhang,Keyan Salari,Chin-Lee Wu,Mark A. Randolph,David T. Scadden,Douglas M. Dahl,John Shin,Peter V. Kharchenko,Philip J. Saylor,David B. Sykes,Ninib Baryawno

DOI: https://doi.org/10.1186/s13073-023-01272-6

IF: 15.266

2024-01-31

Genome Medicine

Abstract:Despite therapeutic advances, once a cancer has metastasized to the bone, it represents a highly morbid and lethal disease. One third of patients with advanced clear cell renal cell carcinoma (ccRCC) present with bone metastasis at the time of diagnosis. However, the bone metastatic niche in humans, including the immune and stromal microenvironments, has not been well-defined, hindering progress towards identification of therapeutic targets.

genetics & heredity
The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern

Thiru Prasanna,Christos S Karapetis,David Roder,Jeanne Tie,Robert Padbury,Timothy Price,Rachel Wong,Jeremy Shapiro,Louise Nott,Margaret Lee,Yu Jo Chua,Paul Craft,Cynthia Piantadosi,Michael Sorich,Peter Gibbs,Desmond Yip

DOI: https://doi.org/10.1080/0284186X.2018.1487581

Abstract:Background: Pattern of spread in patients with metastatic colorectal cancer (mCRC) is variable and may reflect different biology in subsets of patients. This is a retrospective study to explore the outcome of patients with mCRC based on their site of metastasis at diagnosis and to explore the association between tumor characteristics [KRAS/RAS, BRAF, mismatch repair (MMR) status, site of primary] and the site of metastasis. Methods: Patients from two Australian databases were divided into six groups based on site of metastasis at time of diagnosis of metastatic disease; lung-only, liver-only, lymph node-only or any patients with brain, bone or peritoneal metastases. Primary endpoint was overall survival (OS) of each cohort compared with the rest of the population. A Mantel-Haenszel chi-squared test used to explore the association between site of metastasis and selected tumor characteristics. Results: Five thousand nine hundred and sixty-seven patients were included. In a univariate analysis, median OS was significantly higher when metastases were limited to lung or liver and shorter for those with brain, bone or peritoneal metastases (p < .001) in both datasets. BRAF mutation was strongly associated with peritoneal metastases (relative risk = 1.8, p < .001) with lower incidence of lung (RR = 0.3, p = .004) and liver (RR = 0.7, p = .005) limited metastases. Lung-only metastases were more frequent with KRAS/RAS mutation (RR = 1.4, p = .007). Left colon tumors were associated with bone (RR = 1.6, p < .001) and lung-only metastases (RR = 2.3, p = .001) while peritoneal spread was less frequent compared with right colon tumors (RR = 0.6, p < .001). Rectal cancer was associated with brain, bone and lung metastases (RR = 1.7; p = .002, 1.7; p < .001, 2.0; p < .001). Liver-only metastases were less frequent in deficient MMR tumors (RR = 0.7, p = .01). Conclusion: Survival duration with mCRC is related to the site of metastases with lung limited disease showing a more favorable survival outcome compared to other single metastatic site disease. The BRAF mutation and primary rectal cancer were associated with poor prognostic metastatic sites.
Genomic Characterization of Metastatic Lung Cancers.

Hui Yu,Hua Bao,Yulin Wei,Min Wu,Shuyu Wu,Xue Wu,Yang Shao,Xinmin Zhao

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.9584

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:9584 Background: Lung carcinomas are most often diagnosed at stage IV, with metastases, which contribute to 90% of deaths of patients. Enormous efforts have been made in previous studies in seek of underlying mechanisms and treatments that prevent or cure metastases. However, few comprehensive conclusions have been drawn on organ-specific genomic landscapes and molecular dependencies of lung cancer metastases, largely due to limited sample sizes. Methods: We employed massive targeted next generation sequencing (NGS) with a panel covering 425 cancer-related genes on 10409 samples from 8619 patients with lung cancer, including 8479 from primary tumors and 1930 from metastases to the brain, liver, pleura, bones, and lymph nodes. We investigated single nucleotide variants (SNVs), copy number variants (CNVs), structural variations (SVs), mutational signatures, and other genomic characteristics at all primary and metastatic sites. With data of primary-metastatic tumor pairs, we also examined genomic evolutionary patterns. Results: Our data revealed that metastases harbored more instable and complicated genomes. Most SNVs (5/6), CNVs (41/47), and SVs (2/3) that showed significant differences of prevalence between primary tumors (PTs) and metastases (MTs) were MT-enriched. Among them, we identified a novel MT-enriched event, PTK2 amplification (2.33 folds), as well as known ones including mutations of TP53, ARID1A, and BRCA1 (1.23, 1.74, and 2.29 folds) , and amplifications of MYC, RICTOR, and EGFR (2.04, 2.15, and 1.59 folds). In addition, almost all actionable CNV alterations (6/7) showed higher frequencies in MTs. ALK fusions and EGFR mutations, which indicate distinct target therapies, exhibited opposite preference in MTs and PTs, respectively. We also identified MT site-specificity of alterations, such as NF2, TSC2, and LRP1B mutations enriched in the brain, BRAF and GNAS mutations absent in the liver, and APOBEC-associated mutational signatures enriched in lymph nodes. Moreover, we unraveled organ-specific patterns of genomic evolutionary trajectories in metastatic diseases. Conclusions: The genomic profile and evolutionary pattern of metastatic lung cancer differed from that of primary tumors. The identification of site-specific characteristics that may have empowered directional metastasis, such as NF2, TSC2, and LRP1B mutations in the brain and APOBEC-associated mutational signatures in lymph nodes, may guide personalized disease management, design of clinical trials, and/or discovery of therapeutic targets for metastatic lung cancer at different body regions.
Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Xue Wang,Lin Qian,Zengxing Qian,Qihang Wu,Dongying Cheng,Junjun Wei,Lingmin Song,Shuaihuai Huang,Xiaodong Chen,Ping Wang,Guobin Weng

DOI: https://doi.org/10.1097/md.0000000000038268

IF: 1.6

2024-05-26

Medicine

Abstract:Renal cell carcinoma (RCC) stands among the top 10 malignant neoplasms with the highest fatality rates. It exhibits pronounced heterogeneity and robust metastatic behavior. Patients with RCC may present with solitary or multiple metastatic lesions at various anatomical sites, and their prognoses are contingent upon the site of metastasis. When deliberating the optimal therapeutic approach for a patient, thorough evaluation of significant risk factors such as the feasibility of complete resection, the presence of oligometastases, and the patient's functional and physical condition is imperative. Recognizing the nuanced differences in RCC metastasis to distinct organs proves advantageous in contemplating potential treatment modalities aimed at optimizing survival outcomes. Moreover, discerning the metastatic site holds promise for enhancing risk stratification in individuals with metastatic RCC. This review summarizes the recent data pertaining to the current status of different RCC metastatic sites and elucidates their role in informing clinical management strategies across diverse metastatic locales of RCC.

medicine, general & internal
Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma

Matthew Bootsma,Rana R. McKay,Hamid Emamekhoo,Rory M. Bade,Jennifer L. Schehr,Matthew C. Mannino,Anupama Singh,Serena K. Wolfe,Zachery D. Schultz,Jamie Sperger,Wanling Xie,Sabina Signoretti,Christos E. Kyriakopoulos,David Kosoff,Edwin J. Abel,Kyle T. Helzer,Nicholas Rydzewski,Hamza Bakhtiar,Yue Shi,Grace Blitzer,Michael Bassetti,John Floberg,Menggang Yu,Nan Sethakorn,Marina Sharifi,Paul M. Harari,Toni K. Choueiri,Joshua M. Lang,Shuang G. Zhao

DOI: https://doi.org/10.1200/jco.22.00219

IF: 45.3

2022-05-28

Journal of Clinical Oncology

Abstract:PURPOSE Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key immune-tumor interactions. Unlike metastatic tissue biopsies, serial real-time profiling of mRCC is feasible with our noninvasive circulating tumor cell (CTC) approach. METHODS We collected 457 longitudinal liquid biopsies from 104 patients with mRCC enrolled in one of two studies, either a prospective cohort or a phase II multicenter adaptive immunotherapy trial. Using a novel CTC capture and automated microscopy platform, we profiled CTC enumeration and expression of HLA I and programmed cell death-ligand 1 (PD-L1). Given their diametric immunological roles, we focused on the HLA I to PD-L1 ratio (HP ratio). RESULTS Patients with radiographic responses showed significantly lower CTC abundances throughout treatment. Furthermore, patients whose CTC enumeration trajectory was in the highest quartile (> 0.12 CTCs/mL annually) had shorter overall survival (median 17.0 months v 21.1 months, P < .001). Throughout treatment, the HP ratio decreased in patients receiving immunotherapy but not in patients receiving tyrosine kinase inhibitors. Patients with an HP ratio trajectory in the highest quartile (≥ 0.0012 annually) displayed significantly shorter overall survival (median 18.4 months v 21.2 months, P = .003). CONCLUSION In the first large longitudinal CTC study in mRCC to date to our knowledge, we identified the prognostic importance of CTC enumeration and the change over time of both CTC enumeration and the HP ratio. These insights into changes in both tumor burden and the molecular profile of tumor cells in response to different treatments provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.

oncology
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy

Lisha Wang,Sean R Williamson,Mingsheng Wang,Darrell D Davidson,Shaobo Zhang,Lee Ann Baldridge,Xiang Du,Liang Cheng

DOI: https://doi.org/10.1186/1476-4598-13-39

IF: 37.3

2014-01-01

Molecular Cancer

Abstract:Background Renal cell carcinoma (RCC) is known for its ability to metastasize synchronously or metachronously to various anatomic sites. Distinguishing histologic subtypes of metastatic RCC has become increasingly important, as prognosis and therapy can differ dramatically between subtypes. We propose a combination of immunohistochemistry (IHC) and molecular cytogenetics for subtyping metastatic RCC in light of these potential therapeutic implications. Results Specimens from 103 cases of metastatic RCC were retrieved, including 32 cases originally diagnosed as metastatic clear cell renal cell carcinoma (CCRCC), 8 as metastatic papillary renal cell carcinoma (PRCC), and 63 metastatic RCC without a specific subtype. Immunohistochemistry was performed with antibodies against cytokeratin 7 (CK7) and alpha-methylacyl-CoA racemase (AMACR). Dual color interphase fluorescence in situ hybridization was utilized to assess for deletion of chromosome 3p and trisomy of chromosomes 7 and 17 in all tumors. Chromosome 3p deletion was detected in 41% of all metastatic RCC specimens, and trisomy of chromosomes 7 and/or 17 was detected in 16%. Of metastatic CCRCC, chromosome 3p deletion was detected in 63%. Of metastatic PRCC, 75% showed trisomy of chromosomes 7 and/or 17. Of the tumors not previously classified, 6% were positive for CK7, and 64% were positive for AMACR; 35% showed chromosome 3p deletion, and 16% showed trisomy of chromosomes 7 and/or 17. Combined analysis of immunohistochemistry and cytogenetics enabled reclassification of 52% of these metastatic tumors not previously classified. Conclusion Our findings support the utility of immunohistochemistry and cytogenetics for subtyping metastatic RCC.
Abstract 4978: Genomic characterization of metastatic pancreatic cancer according to tumor sample sites

Suleyman Y. Goksu,Muhammet Ozer,Busra Bacik Goksu,Nina N. Sanford,Amy Jones,Nilesh Verma,Syed Kazmi

DOI: https://doi.org/10.1158/1538-7445.am2024-4978

IF: 11.2

2024-03-23

Cancer Research

Abstract:Background: Our research aimed to evaluate and compare the genetic variations in the primary and metastatic sites of patients with metastatic pancreatic cancer. Methods: In this study, we selected individuals with metastatic pancreatic cancer from the data provided by the American Association for Cancer Research Project GENIE (version 14.1). The comparison of genetic mutations between primary and metastatic tumor sites was conducted using the Fisher exact test, augmented with the Benjamini-Hochberg adjustment technique. Results: In a study of 3,108 patients with metastatic pancreatic cancer, 38.9% had metastatic site tumor samples, while 61.1% had samples from the primary tumor. The most frequent mutations were KRAS (89.4%), TP53 (72.9%), SMAD4 (21.2%), and CDKN2A (17.4%). Metastatic samples showed higher rates of CDKN2A, CDKN2B, and MTAP mutations compared to primary site samples (40.1% vs. 29.1%; 20.3% vs. 10.4%; and 20.8% vs. 8.9%, respectively, all with p<0.001 and q<0.001). In patients with young-onset pancreatic cancer (younger than 50 years), there was no notable difference in gene mutations between the two sample groups. Conclusion: Our findings corroborate the notion that identifying the precise genes that contribute to the development of metastatic pancreatic cancer is vital for gaining a more comprehensive understanding of the biological mechanisms. Moreover, genomic profiling could be a key in pinpointing potential biomarkers for diagnosis and therapy. Citation Format: Suleyman Y. Goksu, Muhammet Ozer, Busra Bacik Goksu, Nina N. Sanford, Amy Jones, Nilesh Verma, Syed Kazmi. Genomic characterization of metastatic pancreatic cancer according to tumor sample sites [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4978.

oncology
Multilayered Molecular Profiling Supported the Monoclonal Origin of Metastatic Renal Cell Carcinoma.

Yi Huang,Shengjie Gao,Song Wu,Pengfei Song,Xiaojuan Sun,Xueda Hu,Shiqiang Zhang,Yuan Yu,Jialou Zhu,Cailing Li,Zike Qin,Liangfu Xie,Qiong Yao,Aifa Tang,Zesong Li,Guangwu Guo,Shengqing Wan,Pei Dong,Liang Sun,Weiping Li,Daping Wang,Yaoting Gui,Huanming Yang,Fangjian Zhou,Xiuqing Zhang,Zhiming Cai

DOI: https://doi.org/10.1002/ijc.28654

2014-01-01

International Journal of Cancer

Abstract:Primary renal cell carcinomas (pRCCs) have a high degree of intratumoral heterogeneity and are composed of multiple distinct subclones. However, it remains largely unknown that whether metastatic renal cell carcinomas (mRCCs) also have startling intratumoral heterogeneity or whether development of mRCCs is due to early dissemination or late diagnosis. To decipher the evolution of mRCC, we analyzed the multilayered molecular profiles of pRCC, local invasion of the vena cava (IVC), and distant metastasis to the brain (MB) from the same patient using whole‐genome sequencing, whole‐exome sequencing, DNA methylome profiling, and transcriptome sequencing. We found that mRCC had a lower degree of heterogeneity than pRCC and was likely to result from recent clonal expansion of a rare, advantageous subclone. Consequently, some key pathways that are targeted by clinically available drugs showed distinct expression patterns between pRCC and mRCC. From the genetic distances between different tumor subclones, we estimated that the progeny subclone giving rise to distant metastasis took over half a decade to acquire the full potential of metastasis since the birth of the subclone that evolved into IVC. Our evidence supported that mRCC was monoclonal and distant metastasis occurred late during renal cancer progression. Thus, there was a broad window for early detection of circulating tumor cells and future targeted treatments for patients with mRCCs should rely on the molecular profiles of metastases.
Abstract 3786: Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences

Nerma Crnovrsanin,Soufyan Lakbir,Renske d. Wit,Steven L. Ketelaars,Niels F. Kok,Petur Snaebjornsson,Gerrit A. Meijer,Sanne Abeln,Remond J. Fijneman

DOI: https://doi.org/10.1158/1538-7445.am2024-3786

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Background: Metastasis in colorectal cancer (CRC) is a critical factor in patient outcomes, with 20% of patients affected at the time of diagnosis and up to 50% developing metachronous metastatic disease later on. Despite the growing importance of metastatic sites as independent predictors of overall survival (OS) and the ongoing development of new treatments, there has been limited effort to personalize systemic treatment based on specific metastatic locations. Aim: This study aims to compare the genomic landscape of different metastatic sites in CRC to detect novel diagnostic and therapeutic targets. Methods: DNA whole-genome-sequencing and RNA gene expression data from metastatic CRC samples were retrieved from the Hartwig Medical Foundation (HMF). Single nucleotide variants (SNVs), somatic copy number aberrations (SCNAs) and structural variants (SVs) were reported by HMF with their pipelines. In addition, focal amplifications and deletions were identified using GISTIC2 (v6.15.30). We included 464 microsatellite stable samples derived from liver metastases (n=369), peritoneal metastases (n=58) and lung metastases (n=37). We compared DNA mutation frequencies between tumors from different metastatic sites (two-sided Mann-Whitney tests) and performed differential gene expression and pathway enrichment analysis. Results: Liver metastases had the highest number of focal SCNAs per sample (median 33 vs 17 in peritoneum (p < 0.001); vs 18 in lung (p < 0.001)). Furthermore, we observed 39 site-specific SCNAs in liver, 9 in peritoneal and 15 in lung metastases. Of these, the most significant focal SCNAs were an amplification within 20q13.12 (79%) and deletion within 1p35.3 (64%) in peritoneal metastases and a deletion within 18q21.1 (84%) in lung metastases. Furthermore, peritoneal metastases displayed less genomic instability, featuring lower ploidy (median 2.65 vs 2.94 in liver (p=0.025); vs 3.15 in lung (p=0.025)) and lower aneuploidy scores (median 19 vs 26 in liver (p=0.016); vs 30 in lung (p=0.016)) while having no significant differences in tumor mutational burden or individual SNVs. Analysis of SVs revealed that peritoneal metastases exhibited fewer deletions (≥10kb; 1.3x fold change increase in liver and lung) and fewer duplications (≥1kb; 1.4x fold change increase in liver). Differential gene expression analysis uncovered higher expression of gene sets involved in the apical junction and the TGF-beta-signaling pathway in peritoneal metastases. Conclusion: Specific focal SCNA and differences in genomic instability exhibit an association with preferential organotropism in CRC metastasis and could offer potential targets for the development of new diagnostic and therapeutic approaches. Citation Format: Nerma Crnovrsanin, Soufyan Lakbir, Renske d. Wit, Steven L. Ketelaars, Niels F. Kok, Petur Snaebjornsson, Gerrit A. Meijer, Sanne Abeln, Remond J. Fijneman. Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3786.

oncology
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal

Samra Turajlic,Hang Xu,Kevin Litchfield,Andrew Rowan,Tim Chambers,Jose I. Lopez,David Nicol,Tim O’Brien,James Larkin,Stuart Horswell,Mark Stares,Lewis Au,Mariam Jamal-Hanjani,Ben Challacombe,Ashish Chandra,Steve Hazell,Claudia Eichler-Jonsson,Aspasia Soultati,Simon Chowdhury,Sarah Rudman,Joanna Lynch,Archana Fernando,Gordon Stamp,Emma Nye,Faiz Jabbar,Lavinia Spain,Sharanpreet Lall,Rosa Guarch,Mary Falzon,Ian Proctor,Lisa Pickering,Martin Gore,Thomas B.K. Watkins,Sophia Ward,Aengus Stewart,Renzo DiNatale,Maria F. Becerra,Ed Reznik,James J. Hsieh,Todd A. Richmond,George F. Mayhew,Samantha M. Hill,Catherine D. McNally,Carol Jones,Heidi Rosenbaum,Stacey Stanislaw,Daniel L. Burgess,Nelson R. Alexander,Charles Swanton,PEACE,the TRACERx Renal Consortium

DOI: https://doi.org/10.1016/j.cell.2018.03.057

IF: 64.5

2018-04-01

Cell

Abstract:Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with metastatic ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, and we identify 9p loss as a highly selected event driving metastasis and ccRCC-related mortality (p = 0.0014). Distinct patterns of metastatic dissemination were observed, including rapid progression to multiple tissue sites seeded by primary tumors of monoclonal structure. By contrast, we observed attenuated progression in cases characterized by high primary tumor heterogeneity, with metastatic competence acquired gradually and initial progression to solitary metastasis. Finally, we observed early divergence of primitive ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases.

cell biology,biochemistry & molecular biology
Combinatorial materials research applied to the development of new surface coatings I: a multiwell plate screening method for the high-throughput assessment of bacterial biofilm retention on surfaces.

S. Stafslien,J. Bahr,J. M. Feser,J. Weisz,B. Chisholm,T. E. Ready,P. Boudjouk

DOI: https://doi.org/10.1021/CC050047M

2006-03-01

Journal of Combinatorial Chemistry

Abstract:Combinatorial, high-throughput capabilities have been established to aid in the rapid development of new and effective antifouling marine coatings for naval applications. A biological screening process involving marine bacteria was developed that allows for rapid and effective quantification of bacterial biofilm growth and retention on large numbers of coating surfaces in parallel. The screening process involves (1) multiwell plate modifications for coating deposition, (2) deposition of combinatorial coating libraries via an automated liquid dispensing robot, (3) coating thickness measurements of cured coatings, (4) preconditioning of coatings via immersion in deionized water, (5) bacterial incubation, (6) plate processing, and (7) data analysis for identification of promising candidates. The details of the method developed are described in this document.
Abstract 3779: Genomic and clinical characterization of metastatic patterns using real-word data from a large cohort of colorectal cancer patients

Paolo Manca,Ayush V. Kris,Henry Walch,Christopher Fong,Justin Jee,Karl Pichotta,Nikolaus Schultz,Walid K. Chatila,Rona Yaeger,Francisco Sanchez-Vega

DOI: https://doi.org/10.1158/1538-7445.am2024-3779

IF: 11.2

2024-03-24

Cancer Research

Abstract:Background: Colorectal cancers (CRCs) can exhibit disparate metastatic patterns that affect outcomes. We investigated associations between genomic features and organ-specific metastatic tropism and we compared the frequency of actionable alterations detected in patients undergoing longitudinal clinical sequencing. Methods: We analyzed data for 6574 tumors from 6153 CRC patients, including 4510 primary and 2064 metastatic specimens. All patients had microsatellite stable (MSS) disease and were treated at Memorial Sloan Kettering. Paired primary and metastatic samples were available for 203 patients. Tumors were sequenced with MSK-IMPACT, a targeted DNA sequencing assay that identifies genomic alterations in 341-505 genes. Clinical annotations included sex, stage at diagnosis (Dx), and primary tumor location. History of metastatic disease was automatically retrieved from radiology reports using validated natural language processing methods; time to specific-site metastasis was modeled with Cox regression. False discovery rate (FDR) was used to correct for multiple hypothesis testing. The OncoKB knowledge base was used to identify clinically actionable alterations. Results: Liver (n=1068, 51.7%), peritoneal (n=269, 13.0%) and lung metastases (n=263, 12.7%) accounted for the majority of non-primary sequenced specimens. The frequency of actionable alterations (OncoKB Level≥3A) did not vary between unmatched metastatic and primary samples (12.3% vs 11.4%, p=0.302). In primary tumor samples from patients with localized disease at the time of diagnosis, TGFB pathway alterations were associated with increased risk of metastasis to the brain (HR=2.41, p=0.028), bone (HR=2.10, p<0.001), peritoneum (HR=1.82, p=0.001) and liver (HR=1.42, p=0.049). Alterations in the RAS pathway were associated with increased risk of lung (HR=1.47, p=0.009), peritoneum (HR=1.54, p=0.021) and liver (HR=1.44, p=0.026) metastases. By contrast, WNT pathway alterations were associated with a lower risk of developing lung (HR=0.69, p=0.033) and peritoneal metastasis (HR=0.68, p=0.081). Among patients with paired primary and metastatic samples, no significant difference was observed between the frequency of clinically actionable alterations in primary vs. metastatic specimens (16.7% vs. 18.2%, p=0.794). Presence of metastases-private or primary-private alterations did not correlate with site-specific metastasis risk. Conclusions: The risk of developing metastatic disease and organ-specific dissemination might be linked to genomic abnormalities detectable at the localized stage. No significant difference in the frequency of actionable alterations was observed between primary and metastatic CRC samples. Citation Format: Paolo Manca, Ayush V. Kris, Henry Walch, Christopher Fong, Justin Jee, Karl Pichotta, Nikolaus Schultz, Walid K. Chatila, Rona Yaeger, Francisco Sanchez-Vega. Genomic and clinical characterization of metastatic patterns using real-word data from a large cohort of colorectal cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3779.

oncology
Molecular Differences between Hepatic and Extrahepatic Metastases from Left-Sided and Right-Sided Colorectal Cancer: Potential Metastatic and Prognostic Biomarkers

Meiqin Yuan,Jianfei Fang,Li Wang,Rongrong Chen,Haijun Zhong,Hongming Pan,Wangxia Lv

DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.20233711.557

2023-01-01

Journal of biological regulators and homeostatic agents

Abstract:Background: The most significant prognostic variables for colorectal cancer (CRC) are tumor sidedness and patterns of metastatic spread. However, less is known about the differences in the mutational profile of hepatic and extrahepatic metastases between left-sided and right-sided colorectal cancer. To address this knowledge gap, we sought to analyze the association between different metastatic sites and the gene mutational profiles in each population. We aimed to discover the molecular heterogeneity between these two subtypes of colorectal cancer.Methods: We retrospectively analyzed mutations from 185 colorectal cancer patients. The samples for next generation sequencing were primary colon tumor tissues. Formalin-fixed, paraffin-embedded tumor tissues were collected and deep sequencing targeting 1021 genes was conducted to analyze genomic alteration. Correlation analysis was performed by Chi-square or Fisher's exact tests.Results: A total of 185 CRC patients (132 left-sided colon cancer (LCC) and 53 right-sided colon cancer (RCC)) were analyzed. These included 60 patients with (32.4%) solitary liver metastasis (SLM) cohort, 43 patients (23.2%) with multiple liver metastases (MLM) cohort, 56 patients (30.3%) with extrahepatic metastases (EHM) cohort, and 26 patients (14.1%) without metastases (control cohort). Tumor protein 53 (TP53, 88% vs. 68%, p < 0.05) and adenomatous polyposis coli (APC, 78% vs. 58%, p < 0.05) were found to be mutated more frequently in LCC than RCC. In contrast, B-raf murine sarcoma viral oncogene homologue B (BRAF, 5% vs. 11%, p < 0.05), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA, 13% vs. 23%, p < 0.05), lysine demethylase 6A (KDM6A, 1% vs. 8%, p < 0.05), FAT atypical cadherin 2 (FAT2, 2% vs. 11%, p < 0.05), and SRY-box transcription factor 9 (SOX9, 7% vs. 19%, p < 0.05) were more common in RCC patients compared with those with LCC. In LCC, APC was more frequently mutated in SLM, MLM, and control cohorts than in the EHM cohort (85% vs. 83% vs. 90% vs. 57%, p < 0.05). In RCC, the mutation frequencies of APC and PIK3CA were more significant in the SLM cohort when compared to the EHM cohort. However, a converse result was observed for the SMAD family member 4 (SMAD4) gene.Conclusions: These results demonstrate the molecular heterogeneity between hepatic and extrahepatic metastases from left- and right-sided colorectal cancer. These findings could help us better understand the mechanisms underlying tumor metastasis and reveal disparities in survival among metastatic locations.
[Endothelium pharmacology in pulmonary hypertension].

A. Fedorowicz,S. Chłopicki

2005-10-01

Kardiologia Polska

Abstract:The dysfunction of lung endothelium is crucial in the development of pulmonary hypertension. Dysfunction of endothelial synthesis of prostacyclin (PGI2) and nitric oxide (NO) and increased activity of endothelin 1 (ET-1) are connected to the progress of the disease. In this review the authors describe three major mediators of pulmonary endothelium: NO, PGI2 and ET-1. Their role in pulmonary hypertension and possibilities of pharmacological modulation of their activity are also discussed.
Prognostic Molecular Signatures for Metastatic Potential in Clinically Low-Risk Stage I and II Clear Cell Renal Cell Carcinomas

Andrew J Shih,Neal Murphy,Zachary Kozel,Paras Shah,Oksana Yaskiv,Houman Khalili,Anthony Liew,Louis Kavoussi,Simon Hall,Manish Vira,Xin-Hua Zhu,Annette T Lee

DOI: https://doi.org/10.3389/fonc.2020.01383

2020-08-11

Abstract:Introduction: For patients with localized node-negative (Stage I and II) clear cell renal cell carcinomas (ccRCC), current clinicopathological staging has limited predictive capability because of their low risk. Analyzing molecular signatures at the time of nephrectomy can aid in understanding future metastatic potential. Objective: Develop a molecular signature that can stratify patients who have clinically low risk ccRCC, but have high risk genetic changes driving an aggressive metastatic phenotype. Patients, Materials, and Methods: Presented is the differential expression of mRNA and miRNA in 44 Stage I and Stage II patients, 21 who developed metastasis within 5 years of nephrectomy, compared to 23 patients who remained disease free for more than 5 years. Extracted RNA from nephrectomy specimens preserved in FFPE blocks was sequenced using RNAseq. MiRNA expression was performed using the TaqMan OpenArray qPCR protocol. Results: One hundred thirty one genes and 2 miRNA were differentially expressed between the two groups. Canonical correlation (CC) analysis was applied and four CCs (CC32, CC20, CC9, and CC7) have an AUC > 0.65 in our dataset with similar predictive power in the TCGA-KIRC dataset. Gene set enrichment showed CC9 as kidney development/adhesion, CC20 as oxidative phosphorylation pathway, CC32 as RNA binding/spindle and CC7 as immune response. In a multivariate Cox model, the four CCs were able to identify high/low risk groups for metastases in the TCGA-KIRC (p < 0.05) with odds ratios of CC32 = 5.7, CC20 = 4.4, CC9 = 3.6, and CC7 = 2.7. Conclusion: These results identify molecular signatures for more aggressive tumors in clinically low risk ccRCC patients who have a higher potential of metastasis than would be expected.
Mining and validation of prognosis of various visceral metastasis in renal cell carcinoma: a study based on SEER database

Yu Liu,Wenjuan Cheng,Qin Yang,Yucheng Han,Qing Jiang,Yuanyuan Yang,Haimin Zhang

DOI: https://doi.org/10.1007/s13304-023-01703-4

2024-01-02

Updates in Surgery

Abstract:Our study was aimed to analyze a substantial of renal cell carcinoma (RCC) patients, research the high-risk factors and prognostic factors of metastasis, and thoroughly examine the effects of primary site surgery, lymph node dissection (LND), and chemotherapy on the prognosis of different visceral metastases. The baseline characteristics were characterized, and logistic regression was used to predict the risk factors for metastasis. Prognostic factors of metastatic RCC were assessed using batch univariate and multivariate Cox regression, with adjustments made through PSM. Next, the Kaplan–Meier method was employed to assess OS and create the survival curve. Logistic regression identified risk factors for metastasis: male gender [OR, 1.223; P < 0.001], Hist clear (OR, 9.37; P < 0.001), Hist papillary (OR, 2.49; P < 0.001), and TTX (OR, 23.33; P < 0.001). We found several independent prognostic variables: among which chemotherapy (HR, 0.64), local LND (HR, 0.67), and primary site surgery (HR, 0.97) were associated with better OS. Further study results demonstrated that all kinds of visceral metastasis except for liver metastasis in the operation group had substantially better prognoses than those in the non-operation group (P < 0.05). Regional LND had no discernible impact on survival. Patients with liver, lung, and distant lymph node (LN) metastasis benefited from chemotherapy (P < 0.05), but the bone and brain metastasis did not significantly benefit from treatment (P > 0.05). We recommend primary surgery for different types of visceral metastases except liver metastasis. Routine regional LND is not recommended. Chemotherapy should be considered for patients with lung, distant LN, and liver metastases, but not for those with bone and brain metastases.

surgery
Clinical and Pathological Analysis of Renal Cell Carcinoma Bone Metastasis

Z X Huang,Y Q DU,X P Zhang,S J Liu,T Xu

DOI: https://doi.org/10.19723/j.issn.1671-167x.2018.05.008

2018-01-01

Abstract:OBJECTIVE:To analyze the clinical and pathological characteristics of renal cell carcinoma bone metastasis (RCC-BM) patients.METHODS:Data of RCC-BM patients from July 2003 to November 2017 were retrospectively reviewed. The patients' baseline characteristics (age, gender), tumor characteristics [specific sites of bone metastasis, time to bone metastasis (TTBM), imaging features of bone disease, coexistence of other metastasis], as well as pathological features (histological classification of primary and bone metastasis, immunohistochemical stain results) were collected. Descriptive analysis and difference analysis were used.RESULTS:A total of 113 RCC-BM patients were enrolled with the gender ratio (male:female) of 4:1, mean age of 59.39 years, and all present of osteolysis bone lesions. The common sites of bone metastasis were vertebra (46.0%) and pelvis (38.9%). Other distant metastasis sites coexisted in 28.3%, while 48.18% RCC-BM patients presented with synchronous metastasis (TTBM=0). The median TTBM for metachronous metastasis was 48 months. The majority in this cohort were determined to have primary tumor of clear cell carcinoma. After immunohistochemical examination to 104 RCC-BM patients and sub-group analysis, tendencies of higher positive rates of vascular endothelial growth factor (VEGF) was also found in synchronous group (P=0.097) while tendencies of higher positive rates of carbonic anhydrase (CA)-IX was found in the same group (P=0.100). The patients with clear cell RCC-BM had a significantly higher positive expression of epithelial growth factor receptor (EGFR, P<0.05) than those with non-clear cell RCC-BM group.CONCLUSION:More male and younger patients with metastatic lesions in axial skeleton were found in this cohort. Tendencies in the expression of CA-IX and VEGF in different TTBM sub-group and EGFR in different histology-derived subgroup indicate that they might be associated with risk and prognostic factors and support further target therapies of RCC-BM.
Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma

Fen Ma,Shuoer Wang,Lun Xu,Wending Huang,Guohai Shi,Zhengwang Sun,Weiluo Cai,Zhiqiang Wu,Yiming Huang,Juan Meng,Yining Sun,Meng Fang,Mo Cheng,Yingzheng Ji,Tu Hu,Yunkui Zhang,Bingxin Gu,Jiwei Zhang,Shaoli Song,Yidi Sun,Wangjun Yan

DOI: https://doi.org/10.1038/s42003-024-05772-y

IF: 6.548

2024-01-13

Communications Biology

Abstract:Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma. To explore the potential therapeutic targets for bone metastatic renal cell carcinoma, we profile single cell transcriptomes of 6 primary renal cell carcinoma and 9 bone metastatic renal cell carcinoma. We also include scRNA-seq data of early-stage renal cell carcinoma, late-stage renal cell carcinoma, normal kidneys and healthy bone marrow samples in the study to better understand the bone metastasis niche. The molecular properties and dynamic changes of major cell lineages in bone metastatic environment of renal cell carcinoma are characterized. Bone metastatic renal cell carcinoma is associated with multifaceted immune deficiency together with cancer-associated fibroblasts, specifically appearance of macrophages exhibiting malignant and pro-angiogenic features. We also reveal the dominance of immune inhibitory T cells in the bone metastatic renal cell carcinoma which can be partially restored by the treatment. Trajectory analysis showes that myeloid-derived suppressor cells are progenitors of macrophages in the bone metastatic renal cell carcinoma while monocytes are their progenitors in primary tumors and healthy bone marrows. Additionally, the infiltration of immune inhibitory CD47 + T cells is observed in bone metastatic tumors, which may be a result of reduced phagocytosis by SIRPA -expressing macrophages in the bone microenvironment. Together, our results provide a systematic view of various cell types in bone metastatic renal cell carcinoma and suggest avenues for therapeutic solutions.

biology

Pelvic floor muscle training versus watchful waiting or pessary treatment for pelvic organ prolapse (POPPS): design and participant baseline characteristics of two parallel pragmatic randomized controlled trials in primary care.

Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma

Letter to the Editor: Effect of Parathyroidectomy on Renal Function: Dichotomous Results and Confusing Conclusions.

Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions

The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern

Genomic Characterization of Metastatic Lung Cancers.

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review

Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma

Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy

Abstract 4978: Genomic characterization of metastatic pancreatic cancer according to tumor sample sites

Multilayered Molecular Profiling Supported the Monoclonal Origin of Metastatic Renal Cell Carcinoma.

Abstract 3786: Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences

Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal

Combinatorial materials research applied to the development of new surface coatings I: a multiwell plate screening method for the high-throughput assessment of bacterial biofilm retention on surfaces.

Abstract 3779: Genomic and clinical characterization of metastatic patterns using real-word data from a large cohort of colorectal cancer patients

Molecular Differences between Hepatic and Extrahepatic Metastases from Left-Sided and Right-Sided Colorectal Cancer: Potential Metastatic and Prognostic Biomarkers

[Endothelium pharmacology in pulmonary hypertension].

Prognostic Molecular Signatures for Metastatic Potential in Clinically Low-Risk Stage I and II Clear Cell Renal Cell Carcinomas

Mining and validation of prognosis of various visceral metastasis in renal cell carcinoma: a study based on SEER database

Clinical and Pathological Analysis of Renal Cell Carcinoma Bone Metastasis

Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma